This study was a prospective, observational, longitudinal patient survey of 699 adult patients who had not been treated with DUPIXENT prior to this study.10

Surveys were completed at baseline (prior to DUPIXENT treatment) and at Months 1, 2, 3, 6, 9, 12, and 30-36 after initiation of DUPIXENT. Data are from an interim analysis of patients who had completed surveys through 1 month (n=632) and through 30-36 months (n=425). Patient-reported satisfaction with current atopic dermatitis treatment was evaluated using the question “How satisfied are you with your current treatment(s) for atopic dermatitis?” with responses on a 7-point Likert scale that ranged from “extremely satisfied” to “extremely dissatisfied."10

Limitations of analysis:

The survey data were collected from patients who enrolled in the DUPIXENT patient support program, and these patients may have different perceptions of DUPIXENT vs those who did not enroll. Patients who continue to respond to long-term surveys may be self-selecting for favorable effectiveness and safety. As observed data may bias results. Safety and tolerability data were not collected.10,11

Explore Real-world ADULT PATIENT Results